Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis

Published:2021-11-23 Issue:1 Volume:9 Page:191-206
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Conaghan Philip,Cohen Stanley,Burmester Gerd,Mysler Eduardo,Nash Peter,Tanaka Yoshiya,Rigby William,Patel Jayeshkumar,Shaw Tim,Betts Keith A.,Patel Pankaj,Liu Jianzhong,Sun Rochelle,Fleischmann Roy

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-021-00399-5.pdf

Reference50 articles.

1. Radner H, Alasti F, Smolen JS, Aletaha D. Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. Arthritis Res Ther. 2015;17(1):203.

2. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.

3. Krishnan E, Lingala B, Bruce B, Fries JF. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis. 2012;71(2):213.

4. Verstappen SMM. Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism. Best Pract Res Clin Rheumatol. 2015;29(3):495–511.

5. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685–95.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician;Nature Reviews Rheumatology;2024-01-12

2. Rheumatoid arthritis: advances in treatment strategies;Molecular and Cellular Biochemistry;2022-06-21

3. POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL;Annals of the Rheumatic Diseases;2022-05-23

4. OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL;Annals of the Rheumatic Diseases;2022-05-23

5. The safety of antirheumatic drugs;Deutsches Ärzteblatt international;2022-02-11